360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Oxford Biomedica Plc

Type: Company

Name: Oxford Biomedica Plc (Oxford BioMedica plc)

Nationality: United Kingdom

Web Address: http://www.oxfordbiomedica.co.uk/

Fact Sheet: Fact Sheet for Oxford BioMedica plc

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Oxford Biomedica Plc

Oxford BioMedica plc’s “Buy” Rating Reaffirmed at N+1 Singer (OXB)

Oxford BioMedica plc (LON: OXB) Oxford BioMedica plc (LON: OXB) traded up 1.47% on Thursday, hitting GBX 2.1815. Oxford BioMedica plc has a 1-year low of GBX 1.47 and a 1-year high of GBX 2.20. The stock?s 50-day moving average is currently GBX 2.43. ... [Published American Banking News - May 17 2013]

Entities: Oxford Biomedica Plc, Moving Average

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Manufacturing deal hailed by Oxford BioMedica

The head of Oxford BioMedica has highlighted the financial significance of the biopharmaceutical company's multimillion-pound manufacturing tie-up with Novartis.John Dawson, chief executive officer of Oxford BioMedica, made the comments during the company's ... [Published Insider Media Limited - May 16 2013]

Entities: Oxford Biomedica Plc, Manufacturing, Lentivector, John Dawson, Novartis AG

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Oxford Biomedica focused on RetinoStat Phase 1 study

StockMarketWire.com - Oxford BioMedica said it is focused on completing the RetinoStat Phase I study, generating further income from manufacturing, alliances and intellectual property, as well as initiating pre-clinical development of the next generation ... [Published Stock Market Wire - May 16 2013]

Entities: Oxford Biomedica Plc, Phase I, Manufacturing, John Dawson

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Novartis AG

Oxford Biomedica PLC : Interim Management Statement

Oxford BioMedica Interim Management Statement Oxford, UK - 16 May 2013: OPERATIONAL HIGHLIGHTS LentiVector$ platform manufacturing $ New manufacturing collaboration with Novartis expected to generate between $2.5 million to $4 million of income over the ... [Published Investegate - May 16 2013]

Entities: Oxford Biomedica Plc, Lentivector, Novartis AG

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Manufacturing

OXFORD BIOMEDICA PLC : Oxford BioMedica Interim Management Statement

Oxford BioMedica plc : Oxford BioMedica Interim Management Statement16/05/2013Oxford, UK - 16 May 2013: Oxford BioMedica ("Oxford BioMedica or "the Company) (LSE: OXB), the leading gene-based biopharmaceutical company, today publishes its interim management ... [Published 4 Traders - May 16 2013]

Entities: Oxford Biomedica Plc, Manufacturing, Novartis AG, Antibody

First reported May 09 2013 - Updated May 09 2013 - 2 reports

Oxford BioMedica PLC Announces Update From Association for Research in Vision & Ophthalmology 2013

/PRNewswire/ -- -- UshStatÂ® video selected to showcase theme of "Life-changing Research" -- Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces an update from the 2013 ... [Published BioSpace - May 09 2013]

Entities: Oxford Biomedica Plc, Ophthalmology, Seattle

First reported May 04 2013 - Updated May 04 2013 - 1 reports

United Kingdom : OXFORD BIOMEDICA wins NOVARTIS contract [Te. . .

United Kingdom : OXFORD BIOMEDICA wins NOVARTIS contract [TendersInfo (India)]Al Bawaba Ltd.The bio pharmaceutical company Oxford BioMedica has been selected by healthcare specialist Novartis to make batches of a lentiviral vector for immunotherapy programmes ... [Published Equities.com - May 04 2013]

Entities: Oxford Biomedica Plc, Novartis AG, United Kingdom, John Dawson, Immunotherapy

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Switzerland : NOVARTIS signs up OXFORD BIOMEDICA [TendersInf. . .

Switzerland : NOVARTIS signs up OXFORD BIOMEDICA [TendersInfo (India)]Al Bawaba Ltd.Swiss pharmaceutical giant Novartis has selected biotech company Oxford Biomedica to offer its gene delivery technology for a programme aimed at various forms of leuk ... [Published Equities.com - May 03 2013]

Entities: Oxford Biomedica Plc, Novartis AG, Switzerland, Lentivector, John Dawson

First reported May 03 2013 - Updated May 03 2013 - 1 reports

OXFORD BIOMEDICA PLC : Holding(s) in Company

(4-traders.com)?TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi...http://www.4-traders.com/OXFORD-BIOMEDICA-PLC-4001068/news/OXFORD-BIOMEDICA-PLC-Holding-s-in-Company-168 ... [Published 4 Traders - May 03 2013]

Entities: Oxford Biomedica Plc

First reported May 03 2013 - Updated May 03 2013 - 2 reports

OXFORD BIOMEDICA PLC : Director/PDMR Shareholding

Notification in respect ofNotification in respect of holdings of persons in 4 above6Description of sharesOxford BioMedica PLC ordinary shares of 1p each7Name of registered shareholders and number of sharesOxford BioMedica PLCReason for notificationNotification ... [Published 4 Traders - May 03 2013]

Entities: Oxford Biomedica Plc, Vulpes, Life Science

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Oxford BioMedica in major manufacturing tie-up

Oxford BioMedica has agreed a multimillion-pound deal to manufacture clinical materials.The biopharmaceutical company has been invited by healthcare specialist Novartis to produce batches of a lentiviral vector for immunotherapy programmes in a deal worth ... [Published Insider Media Limited - May 02 2013]

Entities: Oxford Biomedica Plc, Manufacturing, Novartis AG, John Dawson

First reported May 01 2013 - Updated May 01 2013 - 9 reports

Oxford BioMedica to supply vector to Novartis

Oxford BioMedica Plc has signed a contract with Novartis to supply the Swiss company with lentiviral vector material for clinical trials involving a new immunotherapy. The contract is valued at up to £4 million.Full text available to subscribers only. ... [Published MedNous - May 01 2013]

Entities: Oxford Biomedica Plc, Vector, Novartis AG

Quotes

...It now believes that "The Japanese economy is picking up slowly" while in April it remarked that "The Japanese economy is showing movements of picking up recently, while weakness can be seen in some areas."

London close: Footsie closes at 12 year highs [Published Yahoo! UK and Ireland - May 20 2013]

"We believe this not only validates our manufacturing capabilities, but is also a key step towards turning Oxford BioMedica into a company that is financially self-sustaining."

Manufacturing deal hailed by Oxford BioMedica [Published Insider Media Limited - May 16 2013]

...made a strong start to 2013 having secured a revenue-generating lentiviral vector manufacturing alliance," said CEO John Dawson in a statement. "We believe this not only validates our manufacturing capabilities, but is also a key step towards turning Oxford BioMedica into a company that is financially self-sustaining. "Having extended our financial resources into Q2 2014, we look forward to opportunities ahead and remain confident in our ability to deliver our strategic goals." At 8:35am: [LON:OXB] Oxford BioMedica share price was +0.03p at 2.18p Story provided by StockMarketWire.com"

Oxford Biomedica focused on RetinoStat Phase 1 study [Published Stock Market Wire - May 16 2013]

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "We have made a strong start to 2013 having secured a revenue-generating lentiviral vector manufacturing alliance. We believe this not only validates our manufacturing capabilities, but is also a key step towards turning Oxford BioMedica into a company that is financially self-sustaining. Having extended our financial resources into Q2 2014, we look forward to opportunities ahead and remain confident in our ability to deliver our strategic goals."

OXFORD BIOMEDICA PLC : Oxford BioMedica Interim Management Statement [Published 4 Traders - May 16 2013]

More Content

sort by: Date \| Relevance
Motor Neurone Diseases Pipeline Examined in Ins... [Published Business Wire - May 21 2013]
Chasing the cure for Parkinson’s disease [Published PMLive - May 21 2013]
London close: Footsie closes at 12 year highs [Published Yahoo! UK and Ireland - May 20 2013]
London close: Things could be worse (and better) [Published QCK.com - May 18 2013]
Oxford BioMedica plc’s “Buy” Rating Reaffirmed ... [Published American Banking News - May 17 2013]
Equities Research Analysts’ Ratings Reiteration... [Published American Banking News - May 16 2013]
Manufacturing deal hailed by Oxford BioMedica [Published Insider Media Limited - May 16 2013]
Oxford Biomedica focused on RetinoStat Phase 1 ... [Published Stock Market Wire - May 16 2013]
Oxford Biomedica PLC : Interim Management State... [Published Investegate - May 16 2013]
OXFORD BIOMEDICA PLC : Oxford BioMedica Interim... [Published 4 Traders - May 16 2013]
New Report Examines Therapeutic Cancer Vaccine ... [Published Pharma-Mag - May 15 2013]
Actavis Confirms District Court Ruling In Gener... [Published BioMedReports - May 10 2013]
Oxford BioMedica PLC Announces Update From Asso... [Published BioSpace - May 09 2013]
Oxford BioMedica Announces Update from ARVO 2013 [Published Bio-Medicine - May 09 2013]
Oxford BioMedica Announces Update from ARVO 2013 [Published PR Newswire: General Business - May 09 2013]
Polar Cap Gbl Healthcare Growth&IT - Half Yearl... [Published Morningstar UK - May 09 2013]
This week: Investment boosts DGP, IDEA exceeds ... [Published Proactiveinvestors United Kingdom RSS feed - May 08 2013]
London midday: Stocks firmer as policy makers m... [Published Yahoo! UK and Ireland - May 07 2013]
London open: Buying interest on the rise in com... [Published London South East - May 07 2013]
Parkinson's Therapeutics Reviewed by NeuroPersp... [Published NewsBlaze - May 06 2013]
Parkinsons Therapeutics Reviewed by NeuroPerspe... [Published Street Insider - May 06 2013]
Parkinson's Therapeutics Reviewed by NeuroPersp... [Published TickerTech.com - May 06 2013]
United Kingdom : OXFORD BIOMEDICA wins NOVARTIS... [Published Equities.com - May 04 2013]
Switzerland : NOVARTIS signs up OXFORD BIOMEDIC... [Published Equities.com - May 03 2013]
OXFORD BIOMEDICA PLC : Director/PDMR Shareholding [Published 4 Traders - May 03 2013]
OXFORD BIOMEDICA PLC : Holding(s) in Company [Published 4 Traders - May 03 2013]
Investment Research Weekly Roundup including: N... [Published Proactiveinvestors United Kingdom RSS feed - May 03 2013]
Director/PDMR Shareholding [Published TrustNet - May 03 2013]
Oxford BioMedica in major manufacturing tie-up [Published Insider Media Limited - May 02 2013]
What the other papers say this morning – 2 May ... [Published City A.M. - May 02 2013]

Blogs

sort by: Date \| Relevance
New Report Examines Therapeutic Cancer Vaccine ... [Published Pharma-Mag - May 15 2013] “Therapeutic Cancer Vaccines – Current Status and Future Promise” is the title of a new report by Fran Brown, Senior Advisor at healthcare corporate finance and strategy specialist, Results Healthcare. The report begins by looking at the approval of ...
Clinical Trials About "Oxford Biomedica TroVax ... [Published News from Kidney Cancer Association - Mar 08 2013] We list hundreds of Clinical Trials about "Oxford Biomedica TroVax trialled cancer centre" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily. 03/08/2013 ...

Press Releases

sort by: Date \| Relevance
Motor Neurone Diseases Pipeline Examined in Ins... [Published Business Wire - May 21 2013]
Oxford BioMedica Announces Update from ARVO 2013 [Published PR Newswire: General Business - May 09 2013]